Given the role of iTregs in controlling GVHD, there is an ongoing phase-I trial (NCT01634217) initiated by our institute to test the safety of CD4+ iTregs, generated using sirolimus, TGF-β, and IL-2, when given as GVHD prophylaxis to matched sibling donors along with CNI and mycophenolate thereby reducing the inflammatory environment. Here, CD4 is linked to graft versus host disease.